In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in $15.3mm for ExThera

Executive Summary

ExThera Medical Corp. (medical devices for bloodstream infections and pathogen-reduction in blood banking) raised $15.3mm through the sale of Series B preferred stock and the conversion of a convertible note. New investor Fresenius Medical Care Ventures led and was joined by returning shareholders. According to the Form D, 30 investors participated. The company will use the proceeds for US and European clinical trials, regulatory activities, and to scale manufacturing of its Seraph Microbind affinity blood filter, the only device of its kind for capturing and removing a broad range of sepsis-causing bacteria, viruses, toxins, and pro-inflammatory cytokines from whole blood.
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies